Shattuck Labs, Inc. (STTK)
5.51
-0.14
(-2.56%)
USD |
NASDAQ |
Oct 08, 12:30
Shattuck Labs Shareholders Equity (Quarterly) : 211.14M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 211.14M |
| March 31, 2026 | 95.84M |
| December 31, 2025 | 82.39M |
| September 30, 2025 | 93.24M |
| June 30, 2025 | 57.02M |
| March 31, 2025 | 67.59M |
| December 31, 2024 | 79.63M |
| September 30, 2024 | 96.58M |
| June 30, 2024 | 110.62M |
| March 31, 2024 | 128.81M |
| December 31, 2023 | 144.70M |
| September 30, 2023 | 112.78M |
| June 30, 2023 | 138.46M |
| March 31, 2023 | 157.65M |
| Date | Value |
|---|---|
| December 31, 2022 | 176.16M |
| September 30, 2022 | 199.42M |
| June 30, 2022 | 222.53M |
| March 31, 2022 | 248.94M |
| December 31, 2021 | 271.79M |
| September 30, 2021 | 261.17M |
| June 30, 2021 | 277.09M |
| March 31, 2021 | 298.66M |
| December 31, 2020 | 309.86M |
| September 30, 2020 | 107.74M |
| June 30, 2020 | 119.08M |
| March 31, 2020 | |
| December 31, 2019 | 14.52M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
| Biogen, Inc. | 18.85B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 220.67M |
| Total Liabilities (Quarterly) | 9.531M |
| Debt to Equity Ratio | 0.0127 |
| Current Ratio | 27.59 |
| Net Debt Paydown Yield | 0.01% |